Regulation of x-ray mediated gene expression
    1.
    发明授权
    Regulation of x-ray mediated gene expression 失效
    调节X线介导的基因表达

    公开(公告)号:US5641755A

    公开(公告)日:1997-06-24

    申请号:US278452

    申请日:1994-07-20

    IPC分类号: A61K31/40 A61K41/00 A61K48/00

    摘要: Treatment of cells with ionizing radiation is associated with the production of arachidonic acid. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, protein kinase C induction and tumor necrosis factor gene expression. The addition of inhibitors of lipoxygenase, such as ketoconazole, prior to irradiation reduces the expression of of tumor necrosis factor while maintaining the expression of other radiation inducible genes, such as Egr-1 and c-jun. In contrast, indomethacin, an inhibitor of cyclooxygenase, enhanced the expression of tumor necrosis factor as well as other radiation inducible genes. The results show that lipoxygenase inhibitors are useful in the treatment of radiation-induced mucositis, dermatitis, pneumonitis, proctitis, and esophagitis. which may be due to the production of cytokines such as TNF.

    摘要翻译: 用电离辐射处理细胞与花生四烯酸的生产有关。 磷脂酶A2的抑制消除辐射介导的花生四烯酸生成,蛋白激酶C诱导和肿瘤坏死因子基因表达。 在照射之前加入脂氧合酶抑制剂如酮康唑可降低肿瘤坏死因子的表达,同时保持其他放射诱导基因如Egr-1和c-jun的表达。 相比之下,吲哚美辛是环氧合酶抑制剂,增强了肿瘤坏死因子以及其他辐射诱导基因的表达。 结果表明,脂氧合酶抑制剂可用于治疗放射诱导的粘膜炎,皮炎,肺炎,直肠炎和食道炎。 这可能是由于产生诸如TNF的细胞因子。

    Combination of radiotherapy and anti-angiogenic factors
    7.
    发明授权
    Combination of radiotherapy and anti-angiogenic factors 失效
    放射治疗与抗血管生成因子的联合

    公开(公告)号:US06420335B1

    公开(公告)日:2002-07-16

    申请号:US09334084

    申请日:1999-06-16

    IPC分类号: A01N3718

    摘要: The present invention relates generally to the fields of angiogenesis and cancer therapy. More particularly, it concerns the use of anti-angiogenic factors in cancer therapy. The present invention demonstrates that angiostatin or endostatin can sensitize a cell to radiation therapy. Methods and compositions for inhibiting growth, sensitizing a cell to radiotherapy and treating cancer growth by first inhibiting angiogenesis and then employing radiotherapy are described.

    摘要翻译: 本发明一般涉及血管发生和癌症治疗的领域。 更具体地说,它涉及抗癌血管生成因子在癌症治疗中的应用。 本发明证明血管抑素或内皮抑素可使细胞对放射治疗敏感。 描述了抑制生长的方法和组合物,通过首先抑制血管发生然后使用放射治疗使细胞对放射治疗敏感和治疗癌症生长。

    Activation of Egr-1 promoter by DNA damaging chemotherapeutics
    10.
    发明授权
    Activation of Egr-1 promoter by DNA damaging chemotherapeutics 有权
    通过DNA损伤化学治疗激活Egr-1启动子

    公开(公告)号:US08034791B2

    公开(公告)日:2011-10-11

    申请号:US11467799

    申请日:2006-08-28

    摘要: The present invention relates to methods of inducing expression of a polynucleotide encoding a therapeutic polypeptide, e.g., TNF-α, in a cell comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding the polypeptide, and at least one chemotherapeutic agent, wherein the chemotherapeutic agent induces expression of the polypeptide. The invention also relates to methods of inhibiting a neoplastic cell, comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding TNF-α and a chemotherapeutic agent. The present invention further relates to methods of inhibiting or reducing the growth of a tumor in a subject, comprising co-administering to the subject a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding TNF-α and a chemotherapeutic agent, wherein the co-administration inhibits or reduces the ability of the tumor to grow.

    摘要翻译: 本发明涉及在细胞中诱导编码治疗性多肽(例如TNF-α)的多核苷酸表达的方法,包括使细胞与包含编码多肽的多核苷酸可操作地连接的Egr-1启动子的构建体接触, 至少一种化学治疗剂,其中所述化学治疗剂诱导所述多肽的表达。 本发明还涉及抑制肿瘤细胞的方法,包括使细胞与包含与编码TNF-α的多核苷酸和化学治疗剂可操作地连接的Egr-1启动子的构建体接触。 本发明还涉及抑制或减少受试者中肿瘤生长的方法,包括向受试者共同施用包含与编码TNF-α的多核苷酸和化学治疗剂可操作连接的Egr-1启动子的构建体,其中 共同给药抑制或降低肿瘤生长的能力。